Biotricity’s QQ3 2025 results show a meaningful top-line uptick, with revenue of 3,619,108 and a year-over-year growth rate of 21.73% and a quarter-over-quarter rise of approximately 10.8%. The gross margin improved to 76.37%, driven by product mix and favorable cost of goods sold dynamics, but the company remains unprofitable at the bottom line. Net income declined to -1,229,154, resulting in an earnings per share of -0.0544, while EBITDA registered a small loss of -87,000. The operating loss widened due to persistent SG&A spending, despite a modest reduction in operating expenses from prior periods.
The balance sheet continues to reflect substantial leverage and liquidity constraints. Cash at period-end stood around 509,601, with total debt of 25,455,702 and negative shareholder equity of -29,795,969, indicating a capital structure funded with debt rather than equity and a hefty burden of interest and financing costs. Cash flow from operations was negative at -88,093, and the company posted negative free cash flow of -88,093, underscoring the ongoing burn while revenue scales. Management commentary (where transcripts exist) typically emphasizes Bioflux adoption and remote monitoring opportunities; however, no QQ3 2025 earnings transcript is provided in the data, limiting the ability to quote management verbatim here.
Looking ahead, Biotricity faces a high-risk, high-plex scenario. The growth in revenue demonstrates product demand, but translating that demand into sustained profitability requires either higher operating leverage, cost discipline, reimbursement progress, or additional capital to fund ongoing losses. The company’s near-term investment thesis hinges on expanding Bioflux adoption, reducing unit costs, and achieving a more favorable financing runway. Investors should monitor operating cash burn, any steps toward debt refinancing or equity raises, and the pace of revenue diversification beyond a single product line.